The French NCA rejects a claim for interim measures but holds that a pharmaceutical company may be at fault for promoting the differences between its product and competing generic products whereas such differences have no therapeutic value (Sanofi-Aventis)

Since 1998, the Sanofi-Aventis France laboratory has been marketing an antiplatelet medication, Plavix(r), whose intellectual property protection expired on 15 July 2008 in Europe, with the exception of the rights protecting clopidogrel salt used in Plavix(r) and the clopidogrel-aspirin combination used in the treatment of acute coronary syndrome (ACS). A dozen or so generic specialities, including that of Sanofi-Aventis, have received a marketing authorisation. To promote its

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Vogel & Vogel (Paris)

Quotation

Joseph Vogel, The French NCA rejects a claim for interim measures but holds that a pharmaceutical company may be at fault for promoting the differences between its product and competing generic products whereas such differences have no therapeutic value (Sanofi-Aventis), 17 May 2010, e-Competitions Bulletin Pharma & Dominance, Art. N° 31735

Visites 852

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues